215 FIRST STREET, CAMBRIDGE, MA
Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Annual Report to Security Holders
CEO Departure - Douglas Ingram to Retire by End of 2026
Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Sarepta Therapeutics Enters $291.4M Exchange Agreement for Convertible Notes
Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Equity Awards Granted to CEO Douglas S. Ingram - $12 Million Total Value
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Quarterly Holdings Report for Institutional Managers
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS